利奈唑胺治療重癥肺炎的臨床療效及安全性研究.doc
約6頁(yè)DOC格式手機(jī)打開(kāi)展開(kāi)
利奈唑胺治療重癥肺炎的臨床療效及安全性研究,摘要：為了更加全面深入地了解利奈唑胺醫(yī)治重癥肺炎病人的醫(yī)用價(jià)值，回顧性搜集莆田學(xué)院附屬醫(yī)院的重癥監(jiān)護(hù)科78例病患資料，時(shí)間是2012年3月1日到2013年3月1日的病患資料，并且將病患資料隨機(jī)分成兩組：利奈唑胺治療組和萬(wàn)古霉素對(duì)照組都是39例，觀察分析兩組病患的治療情況。從數(shù)據(jù)...
內(nèi)容介紹
此文檔由會(huì)員 一切如愿8 發(fā)布
利奈唑胺治療重癥肺炎的臨床療效及安全性研究
摘要：為了更加全面深入地了解利奈唑胺醫(yī)治重癥肺炎病人的醫(yī)用價(jià)值，回顧性搜集莆田學(xué)院附屬醫(yī)院的重癥監(jiān)護(hù)科78例病患資料，時(shí)間是2012年3月1日到2013年3月1日的病患資料，并且將病患資料隨機(jī)分成兩組：利奈唑胺治療組和萬(wàn)古霉素對(duì)照組都是39例，觀察分析兩組病患的治療情況。從數(shù)據(jù)統(tǒng)計(jì)的結(jié)果中得知用利奈唑胺治療的病人病情開(kāi)始改善的有效率是69.3%（27/39)、細(xì)菌清除率是58.1%（18/31）;用萬(wàn)古霉素治療的病人病情開(kāi)始改善的有效率是64.1（25/39）、細(xì)菌清除率53.3（16/30）,l,兩個(gè)不同組的數(shù)據(jù)的差異都沒(méi)有統(tǒng)計(jì)學(xué)意義，但是利奈唑胺病人應(yīng)用藥物后有17.9%（7/39）的病患出現(xiàn)不良反應(yīng)，而萬(wàn)古霉素病人應(yīng)用藥物后甚至超過(guò)33.3(13/39)，兩個(gè)數(shù)據(jù)的差異有統(tǒng)計(jì)學(xué)意義。分析兩組治療病患的身體病癥變化情況可以發(fā)現(xiàn)利奈唑胺治療G+菌引起的重癥肺炎的價(jià)值性更高，而且安全性更加的廣泛。
關(guān)鍵詞：療效；利奈唑胺；不良反應(yīng)；
Study on clinical efficacy and safety of linezolid in the treatment of severe pneumonia
Abstract: For a more thorough understanding of medical value of linezolid in treatment of patients with severe pneumonia, the intensive care department of Affiliated Hospital of Putian College were collected retrospectively 78 cases of patient data, time is March 1, 2012 to March 1, 2013 patients, and the patients were randomly divided into two groups: linezolid and vancomycin treatment group control group is 39 cases, observation of the two groups of patients treatment. From the statistical results that the efficient use of linezolid in the treatment of the patient began to improve is 69.3% ( 27\/39 ), the bacterial clearance rate was 58.1% ( 18\/31 ); 64.1 is the effective rate of vancomycin in the treatment of patients condition began to improve ( 25\/39 ), bacterial clearance rate was 53.3 ( 16\/30 ), L, differences between the two different groups of data are not statistically significant, but there are 17.9% linezolid patients using drugs ( 7\/39 ) in patients with adverse reactions, and vancomycin patients using drugs or even more than 33.3 ( 13\/39 ), the difference was statistically significant two data. Analysis of physical symptoms of treatment in the two groups patients can be found by value of linezolid in the treatment of severe pneumonia in G+ bacteria is higher, and safety is more widely.
Keywords: efficacy;linezolid; adverse reaction;
摘要：為了更加全面深入地了解利奈唑胺醫(yī)治重癥肺炎病人的醫(yī)用價(jià)值，回顧性搜集莆田學(xué)院附屬醫(yī)院的重癥監(jiān)護(hù)科78例病患資料，時(shí)間是2012年3月1日到2013年3月1日的病患資料，并且將病患資料隨機(jī)分成兩組：利奈唑胺治療組和萬(wàn)古霉素對(duì)照組都是39例，觀察分析兩組病患的治療情況。從數(shù)據(jù)統(tǒng)計(jì)的結(jié)果中得知用利奈唑胺治療的病人病情開(kāi)始改善的有效率是69.3%（27/39)、細(xì)菌清除率是58.1%（18/31）;用萬(wàn)古霉素治療的病人病情開(kāi)始改善的有效率是64.1（25/39）、細(xì)菌清除率53.3（16/30）,l,兩個(gè)不同組的數(shù)據(jù)的差異都沒(méi)有統(tǒng)計(jì)學(xué)意義，但是利奈唑胺病人應(yīng)用藥物后有17.9%（7/39）的病患出現(xiàn)不良反應(yīng)，而萬(wàn)古霉素病人應(yīng)用藥物后甚至超過(guò)33.3(13/39)，兩個(gè)數(shù)據(jù)的差異有統(tǒng)計(jì)學(xué)意義。分析兩組治療病患的身體病癥變化情況可以發(fā)現(xiàn)利奈唑胺治療G+菌引起的重癥肺炎的價(jià)值性更高，而且安全性更加的廣泛。
關(guān)鍵詞：療效；利奈唑胺；不良反應(yīng)；
Study on clinical efficacy and safety of linezolid in the treatment of severe pneumonia
Abstract: For a more thorough understanding of medical value of linezolid in treatment of patients with severe pneumonia, the intensive care department of Affiliated Hospital of Putian College were collected retrospectively 78 cases of patient data, time is March 1, 2012 to March 1, 2013 patients, and the patients were randomly divided into two groups: linezolid and vancomycin treatment group control group is 39 cases, observation of the two groups of patients treatment. From the statistical results that the efficient use of linezolid in the treatment of the patient began to improve is 69.3% ( 27\/39 ), the bacterial clearance rate was 58.1% ( 18\/31 ); 64.1 is the effective rate of vancomycin in the treatment of patients condition began to improve ( 25\/39 ), bacterial clearance rate was 53.3 ( 16\/30 ), L, differences between the two different groups of data are not statistically significant, but there are 17.9% linezolid patients using drugs ( 7\/39 ) in patients with adverse reactions, and vancomycin patients using drugs or even more than 33.3 ( 13\/39 ), the difference was statistically significant two data. Analysis of physical symptoms of treatment in the two groups patients can be found by value of linezolid in the treatment of severe pneumonia in G+ bacteria is higher, and safety is more widely.
Keywords: efficacy;linezolid; adverse reaction;
